PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 19, 2026Cancer0 citations

Neoadjuvant therapy for patients with nonsmall cell lung cancer: Not as easy in the real world

View Full Paper
GCGiordano Fabricio Cittolin‐SantosARAnjali Rohatgi

Key Points

  • To compare real-world outcomes of neoadjuvant therapy for nonsmall cell lung cancer with trial outcomes.
  • Assessment of outcomes in patients receiving neoadjuvant therapy
  • Comparison to patients in clinical trials
  • Focus on patient selection and presurgical evaluation
  • Real-world outcomes align closely with clinical trial outcomes
  • Effective patient selection enhances therapy completion
  • Importance of presurgical evaluation emphasized to optimize surgery

Abstract

Real‐world outcomes for patients with nonsmall cell lung cancer who receive neoadjuvant therapy are similar to the outcomes of those who received treatment on neoadjuvant and perioperative nonsmall cell lung cancer trials. Careful patient selection and presurgical evaluation is important for ensuring patients are able to complete neoadjuvant therapy and undergo surgery.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Cittolin‐Santos et al. (2026) studied this question.

synapsesocial.com/papers/6996a887ecb39a600b3ef5f5https://doi.org/10.1002/cncr.70312
Ask AI
Helpful
Bookmark
Share
View Full Paper